Welcome to the SWSLHD Libraries Research Repository, an institutional repository which showcases the research output of South Western Sydney Local Health District staff, both past and present. The repository supports the SWSLHD Strategic Plan in their vision for the SWSLHD to be a leader in research and innovation.
Please use this identifier to cite or link to this item:
https://swslhd.intersearch.com.au/swslhdjspui/handle/1/11844| Title: | Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer |
| Authors: | Al-Sohaily, S. Henderson, C. Selinger, C. Pangon, L. Segelov, E. Kohonen-Corish, M. R. J. Warusavitarne, J. |
| SWSLHD Author: | Al-Sohaily, Sam |
| Affiliates: | Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia Department of Gastroenterology, Campbelltown and Fairfield Hospitals, Australia South Western Sydney Clinical School, University of NSW, Australia Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW, Australia Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia School of Medicine, University of Western Sydney, Sydney, NSW, Australia |
| Department: | Fairfield Hospital, Department of General Medicine |
| Issue Date: | 2014 |
| Journal: | Histopathology |
| Publisher: | Blackwell Publishing Ltd |
| Abstract: | Aim: Special AT-rich sequence-binding protein 1 (SATB1) is a cell type-specific matrix attachment region binding protein, functioning as a global genome organizer. This study aims to investigate the expression pattern and the prognostic value of SATB1 in colorectal cancer. Methods and results: Prospectively collected data were obtained and tissue microarrays were constructed from a cohort of 352 patients. SATB1 protein expression was evaluated by immunohistochemistry and scored by two independent investigators. SATB1 expression was predominantly nuclear in both normal and cancer tissues. Loss of SATB1 nuclear expression was seen in 22% of colorectal cancers compared to 1.5% of adjacent normal colorectal tissue, and was associated with worse overall survival (P = 0.02) independent of age and stage of disease (HR 2.48 with 95% CI 1.31-4.70). Loss of SATB1 expression was more evident in younger patients (P = 0.03), tumours with mucinous or signet ring histology (P = 0.0001) and poor differentiation (P = 0.005). SATB1 expression was associated with a survival advantage in patients with Dukes C tumours who received adjuvant chemotherapy. Conclusion: Loss of SATB1 nuclear expression correlates with poor survival and a less favourable response to adjuvant chemotherapy in colorectal cancer. The value of SATB1 in individualized colorectal cancer therapy warrants further evaluation. |
| URI: | https://swslhd.intersearch.com.au/swslhdjspui/handle/1/11844 |
| ISSN: | 03090167 (ISSN) |
| Digital object identifier: | 10.1111/his.12295 |
| Appears in Collections: | Fairfield Hospital Liverpool Hospital |
Files in This Item:
There are no files associated with this item.
Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.
